scholarly journals Drug Reaction With Eosinophilia and Systemic Symptom (DRESS) Following Rifampicin Treatment: A Case Report

Cureus ◽  
2021 ◽  
Author(s):  
Ramesh Shrestha ◽  
Shivendra K Jha ◽  
Jasmine Bartaula
Keyword(s):  
Drug Reaction ◽  
Case Report ◽  
Systemic Symptom ◽  
Rifampicin Treatment

scholarly journals Drug reaction with eosinophilia and systemic symptom induced by carbamazepine: a case report

2019 ◽  
Vol 8 (5) ◽  
pp. 1115
Author(s):  
Rahul R. Damor ◽  
Amita R. Kubavat ◽  
Kiran G. Piparva
Keyword(s):  
Drug Reaction ◽  
Case Report ◽  
Antiepileptic Drugs ◽  
Drug Exposure ◽  
Latency Period ◽  
Systemic Symptom ◽  
Dress Syndrome ◽  
Period 2 ◽  
Life Threatening ◽  
Systemic Symptoms

Drug reaction with eosinophilia and systemic symptoms (DRESS) syndrome is a severe, potentially life-threatening acute adverse drug reaction (ADR), typically characterized by a long latency period (2-6 weeks to 3 months) from drug exposure. DRESS syndrome is defined by the presence of fever, cutaneous eruption, lymphadenopathy, systemic or asymptomatic internal organ involvement (e.g. Hepatitis, carditis, interstitial nephritis, interstitial pneumonitis, etc.) and haematological abnormalities, mainly leucocytosis, eosinophilia and sometimes atypical lymphocytosis. There are around 50 culprit drugs which cause DRESS syndrome e.g. carbamazepine, phenytoin, allopurinol, sulfa derivatives, antidepressants, antiepileptics, non-steroidal anti-inflammatory drugs and antimicrobials. The incidence of DRESS syndrome has been estimated to be between 1 in 1,000 and 1 in 10,000 drug exposures. There are many reported cases of DRESS syndrome due to carbamazepine, phenytoin, vancomycin, levitiracitam, ceftriaxone etc. Author presented a case of DRESS syndrome by carbamazepin. RegiSCAR and Japanese consensus group have developed specific criteria for making the diagnosis of DRESS syndrome. The patient described here met the majority of criteria according to RegiSCAR scoring guidelines for a diagnosis of DRESS syndrome induced by carbamazepine. As per RegiSCAR diagnostic criteria author had concluded that this was a “Definite” case of DRESS (Drug Reaction with Eosinophilia and Systemic Symptom) syndrome induced by carbamazepine. Carbamazepine is most common broad-spectrum antiepileptic drugs so, this case report will raises awareness among physician to suspect DRESS syndrome in patients who present unusual complaints and skin findings after starting antiepileptic drugs.

scholarly journals Drug Reaction with Eosinophilia and Systemic Symptom (DRESS) induced by carbamazepine: a case report and literature review

2014 ◽  
Vol 18 ◽  
Author(s):  
Nissrine EL omairi ◽  
Sanae Abourazzak ◽  
Sanae Chaouki ◽  
Samir Atmani ◽  
Moustapha Hida
Keyword(s):  
Drug Reaction ◽  
Case Report ◽  
Literature Review ◽  
Systemic Symptom

scholarly journals Olanzapine-induced black hairy tongue: a rare case

2017 ◽  
Vol 6 (8) ◽  
pp. 2091
Author(s):  
Vishal P. Giri ◽  
Debranjan Datta ◽  
Parvathi Devi
Keyword(s):  
Bipolar Disorder ◽  
Adverse Drug Reaction ◽  
Drug Reaction ◽  
Case Report ◽  
Dopamine Receptors ◽  
Rare Case ◽  
Second Generation Antipsychotic ◽  
Black Hairy Tongue ◽  
Calming Effect ◽  
Prevention Of Relapse

Olanzapine is second generation antipsychotic drug. It alters affinities for serotonin and dopamine receptors and provides mild sedating and calming effect. It is indicated for the treatment of schizophrenia, acute mania and the prevention of relapse in bipolar disorder. We present a case report of a 65- year- old man with bipolar disorder I, who developed black hairy tongue following treatment with olanzapine and completely recovered after withdrawal of treatment. Awareness about this particular adverse drug reaction will ensure proper management and avoid unnecessary investigations.

Capecitabine-induced myopericarditis – A case report and review of literature

2018 ◽  
Vol 25 (4) ◽  
pp. 1006-1010 ◽  
Author(s):  
Sydney Saunders ◽  
Maria Anwar
Keyword(s):  
Adverse Drug Reaction ◽  
Drug Reaction ◽  
Case Report ◽  
Literature Search ◽  
Case Reports ◽  
Locally Advanced ◽  
Rectal Adenocarcinoma ◽  
Review Of Literature ◽  
Medication Discontinuation ◽  
Laboratory Investigations

Objective To describe a possible case of capecitabine-induced myopericarditis in a patient at the Cardio-Oncology Clinic in Calgary, AB. Design A literature search and adverse drug reaction assessment with the Naranjo tool was conducted. Results A 39-year-old male with recurrent locally advanced rectal adenocarcinoma presented two days after adjuvant treatment with capecitabine and oxaliplatin complaining of intermittent, severe interscapular pain. Based on symptoms, laboratory investigations, and imaging, the patient was diagnosed with acute myopericarditis. Management included aspirin, colchicine, and discontinuing adjuvant chemotherapy. A literature review revealed one case report of capecitabine-induced myopericarditis; however, more data were found regarding the cardiotoxicity of fluorouracil, for which capecitabine is a pro-drug. No case reports were found for oxaliplatin. Conclusion Due to the timeline of capecitabine administration, symptom onset, and improvement upon medication discontinuation, capecitabine is the probable cause of the myopericarditis. Although rare, it is important to consider the possibility of myopericarditis in patients receiving a fluoropyrimidine who present with cardiovascular symptoms.

The association between HLA-B*15:02 and phenytoin-induced severe cutaneous adverse reactions: a meta-analysis

2021 ◽  
Author(s):  
Thanh Huong Phung ◽  
Khanh Ngoc Cong Duong ◽  
Mac Ardy Junio Gloria ◽  
Thien Khac Nguyen
Keyword(s):  
Drug Reaction ◽  
Adverse Reactions ◽  
Meta Analysis ◽  
Stevens Johnson Syndrome ◽  
Random Effects Model ◽  
Systemic Symptom ◽  
Anticonvulsant Agent ◽  
Johnson Syndrome ◽  
Severe Cutaneous Adverse Reactions ◽  
Cutaneous Adverse Reactions

Aim: Phenytoin (PHT) is a common anticonvulsant agent known for inducing severe cutaneous adverse reactions (SCARs). HLA-B*15:02 as a risk factor of PHT-induced SCARs was reported in numerous studies with inconsistent results. This meta-analysis aimed to establish pooling evidence of this association. Materials & methods: Pooled odds ratios (ORs) with 95% CIs were estimated using a random-effects model. Results: A total of 11 studies on 1389 patients, were included for the analyses. There was a significant association between HLA-B*15:02 and PHT-induced SCAR (pooled OR = 2.29, 95% CI: 1.25–4.19, p = 0.008). Furthermore, there was a significant association regarding Stevens–Johnson syndrome/toxic epidermal necrolysis (OR = 3.63, 95% CI: 2.15–6.13, p < 0.001) but no association regarding drug reaction with eosinophilia and systemic symptom. Conclusion: The results supported the recommendations of HLA-B*15:02 screening before treatment with PHT.

scholarly journals A Case of the Drug Reaction with Eosinophilia and Systemic Symptom (DRESS) Following Isoniazid Treatment

2015 ◽  
Vol 78 (1) ◽  
pp. 27 ◽  
Author(s):  
Jin-Yong Lee ◽  
Yun-Jae Seol ◽  
Dong-Woo Shin ◽  
Dae-Young Kim ◽  
Hong-Woo Chun ◽  
...  
Keyword(s):  
Drug Reaction ◽  
Systemic Symptom
Sign in / Sign up

Export Citation Format

Share Document